The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters
Because MOTS-c enhances insulin-independent glucose uptake, patients with type 1 diabetes or those using exogenous insulin should be monitored carefully to prevent hypoglycemia, though this theoretical risk has not materialized in clinical reports to date
Even 20 to 30 minutes of compound movements (squats, deadlifts, presses, rows) stimulates enough muscle protein synthesis to significantly offset the lean mass loss that semaglutide promotes
What are the most common side effects
Multiple inflammation pathways: Both peptides modulate inflammation, but through different mechanisms